Catalyst

Slingshot members are tracking this event:

Karyopharm's STORM Phase 2b Topline Data for Multiple Myeloma Expected Mid Year

Source Link:
http://finance.yahoo.com/news/edited-transcript-kpti-earnings-conference-141721622.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
KPTI
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Clinical Data "Over the next six to 18 months we expect to provide data for a number of studies some of which if positive could serve as the basis for regulatory filings. These trials include STORM in multiple myeloma where we expect Phase 2b topline data with a the primary endpoint of overall response rate from the first 80 patients in mid-2016"
http://finance.yahoo...
Additional Relevant Details  "We remain on track for data readouts from several of our ongoing selinexor studies, including top-line results from the STORM and STOMP studies in relapsed/refractory MM, updated data from the SIGN study in gynecologic malignancies at the European Society of Medical Oncology 2016 Annual Meeting."
http://investors.kar...
Additional Relevant Details " will provide an overview of top-line results from its Phase 2b STORM study and the planned development path for selinexor (KPT-330) in multiple myeloma (MM) on Tuesday, September 6, 2016"
http://investors.kar...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 06, 2016
Occurred Source:
http://www.streetinsider.com/Corporate+News/Karyopharm+Therapeutics+(KPTI)+Announces+Top-Line+Selinexor+Phase+2b+Data+in+Multiple+Myeloma/12002487.html
Related Projects Image
Related Keywords Multiple Myeloma, Storm, Phase 2b Topline Data
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.